On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE:ABBV) is a very solid pharmaceutical company. The company has good dividend yield and attractive valuations, he added.
On Thursday, AbbVie released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FR?) positive, platinum-sensitive ovarian cancer (PSOC).
Bill Baruch of Blue Line Capital said IQVIA Holdings Inc. (NYSE:IQV) has been kind of punished in the recent weeks, ...